Evidence map›Paper›PMID 30184476›Full record

ReviewSeminars in cell & developmental biology2019

Recapitulating kidney development: Progress and challenges.

Melissa H Little, Santhosh V Kumar, Thomas Forbes

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cell & developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Tubuloid culture enables long-term expansion of functional human kidney tubule epithelium from iPSC-derived organoids.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Organs-on-chip technology: a tool to tackle genetic kidney diseases.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Journal of the American Society of Nephrology : JASN · 2020
    Article
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Melissa H LittleMurdoch Children's Research Institute, Flemington Rd, Parkville, Victoria 3052, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3010, Australia; Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: melissa.little@mcri.edu.au.
Santhosh V KumarMurdoch Children's Research Institute, Flemington Rd, Parkville, Victoria 3052, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3010, Australia.
Thomas ForbesMurdoch Children's Research Institute, Flemington Rd, Parkville, Victoria 3052, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3010, Australia; Department of Nephrology, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia.
The University of Melbourne · AURoyal Children's Hospital · AU

Funding

Generating kidney organoids and mature renal cell types via directed iPSC differentiationUH3DK107344 · NIDDK · MURDOCH CHILDREN'S RESEARCH INSTITUTE · PI LITTLE, MELISSA HELEN · 2017 to 2019
$1.0M
Generating kidney organoids and mature renal cell types via directed iPSC differentiationUH2DK107344 · NIDDK · MURDOCH CHILDREN'S RESEARCH INSTITUTE · PI LITTLE, MELISSA HELEN · 2015 to 2016
$691k
NIDDK NIH HHS UH2 DK107344NIDDK NIH HHS UH3 DK107344
6 · The paper itself

Abstract

Decades of research into the molecular and cellular regulation of kidney morphogenesis in rodent models, particularly the mouse, has provided both an atlas of the mammalian kidney and a roadmap for recreating kidney cell types with potential applications for the treatment of kidney disease. With advances in both our capacity to maintain nephron progenitors in culture, reprogram to kidney cell types and direct the differentiation of human pluripotent stem cells to kidney endpoints, renal regeneration via cellular therapy or tissue engineering may be possible. Human kidney models also have potential for disease modelling and drug screening. Such applications will rely upon the accuracy of the model at the cellular level and the capacity for stem-cell derived kidney tissue to recapitulate both normal and diseased kidney tissue. In this review, we will discuss the available cell sources, how well they model the human kidney and how far we are from application either as models or for tissue engineering.

Indexed as

RegenerationAnimalsCell- and Tissue-Based TherapyCell DifferentiationHumansKidneyNephronsPluripotent Stem CellsRenal Insufficiency, ChronicTissue EngineeringDirected differentiationHuman nephron progenitorKidney developmentKidney organoidPluripotent stem cellTransdifferentiation

Identifiers

PMID30184476
PMCPMC6426693
OpenAlexW2891156969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.